C07K 14/5406
Il-4
Official title: {il-4}
C07K14/5406 (Il-4) appears on 261 US grants and 326 published applications in this corpus.
Search patents in C07K- Granted patents
- 261
- Published applications
- 326
- Assignees
- 159
- Inventors
- 543
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 5 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 10 | 0 |
| 1999 | 11 | 0 |
| 2000 | 8 | 0 |
| 2001 | 5 | 2 |
| 2002 | 9 | 5 |
| 2003 | 7 | 18 |
| 2004 | 3 | 15 |
| 2005 | 7 | 15 |
| 2006 | 5 | 6 |
| 2007 | 9 | 22 |
| 2008 | 12 | 16 |
| 2009 | 10 | 9 |
| 2010 | 9 | 9 |
| 2011 | 8 | 14 |
| 2012 | 9 | 4 |
| 2013 | 5 | 8 |
| 2014 | 2 | 7 |
| 2015 | 8 | 9 |
| 2016 | 1 | 11 |
| 2017 | 8 | 11 |
| 2018 | 6 | 7 |
| 2019 | 7 | 14 |
| 2020 | 8 | 15 |
| 2021 | 12 | 17 |
| 2022 | 8 | 26 |
| 2023 | 12 | 13 |
| 2024 | 16 | 26 |
| 2025 | 14 | 14 |
| 2026 | 6 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- IL-10 muteins6 Oct 2026US 12,753,217 B2Universite De Lille
- Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)11 Aug 2026US 12,702,710 B2Medicenna Therapeutics Inc.
- Composition for treating pain26 May 2026US 12,636,346 B2Kolon Life Science, Inc.
- IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof31 Mar 2026US 12,590,133 B2Medicenna Therapeutics Inc.
- Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof17 Feb 2026US 12,552,849 B2Deka Biosciences, Inc.
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Methods and compositions for treating cancer1 Oct 2026US 2026/0297152 A1
- Rna replicons, compositions and methods of use thereof24 Sep 2026US 2026/0286321 A1Able Sciences, Inc.
- Use of immunomodulation methods in combination with cytokine fusions for disease treatment13 Aug 2026US 2026/0232820 A1Medicenna Therapeutics Inc.
- Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof6 Aug 2026US 2026/0226123 A1Deka Biosciences, Inc.
Most cited
By later US patents
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides190US 5,679,647 AThe Regents of the University of California · 1997
- Derivatives of growth hormone and related proteins160US 6,608,183 B1Bolder Biotechnology, Inc. · 2003
- Mammalian interleukin-4156US 5,017,691 ASchering Corporation · 1991
- Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin129US 5,529,915 ASterling Winthrop Inc. · 1996